0001225208-11-011366.txt : 20110406 0001225208-11-011366.hdr.sgml : 20110406 20110406121454 ACCESSION NUMBER: 0001225208-11-011366 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110404 FILED AS OF DATE: 20110406 DATE AS OF CHANGE: 20110406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BERTOLINI ROBERT J CENTRAL INDEX KEY: 0001270263 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 11742493 MAIL ADDRESS: STREET 1: C/O SCHERING PLOUGH CORP STREET 2: 2000 GALLOPING HILL RD CITY: KENILWORTH STATE: NJ ZIP: 070333 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: 500 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml X0303 4 2011-04-04 0000732485 GENZYME CORP GENZ 0001270263 BERTOLINI ROBERT J 500 KENDALL STREET CAMBRIDGE MA 02142 1 Genzyme common stock (GENZ) 2011-04-04 4 M 0 2375.0000 0.0000 A 4750.0000 D Genzyme common stock (GENZ) 2011-04-04 4 D 0 2375.0000 74.0000 D 2375.0000 D Genzyme common stock (GENZ) 2011-04-04 4 U 0 2375.0000 74.0000 D 0.0000 D Restricted Stock Units 0.0000 2011-04-04 4 M 0 2375.0000 0.0000 D Genzyme common stock (GENZ) 2375.0000 0.0000 D Stock Option (right to buy) 51.5200 2011-04-04 4 D 0 7125.0000 51.5200 D 2020-06-16 Genzyme common stock (GENZ) 7125.0000 0.0000 D Stock Option (right to buy) 49.4200 2011-04-04 4 D 0 7125.0000 49.4200 D 2010-05-20 2019-12-08 Genzyme common stock (GENZ) 7125.0000 0.0000 D The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders. This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option. Susan P. Cogswell, Attorney-in-Fact 2011-04-06